专利检索_ .产生5'磷酸单酯的核糖核酸内切酶专利检索_ .产生5'磷酸单酯的核糖核酸内切酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	新型毒素-抗毒素系统	CN200980137525.7	2009-08-20	CN102164950A	2011-08-24	井上正顺; 山口芳广
在某些实施方案中公开了抑制细胞功能的方法，其包括诱导在GCU处切割mRNA的mRNA干扰酶的表达。
2	COMPOSITIONS AND METHODS FOR DELIVERING MICRORNA	US15122381	2015-03-11	US20160369272A1	2016-12-22	Florence M. HOFMAN; Raquel M.S. FERREIRA; Steven L. GIANNOTTA; Thomas C. CHEN
The invention relates to compositions, methods and kits for using Argonaute-2 (Ago-2) as a systemic carrier to deliver a miRNA to an endothelial cell. The invention also relates to compositions, methods and kits for inhibiting angiogenesis and/or treating a condition by using Ago-2 as a systemic carrier to deliver a miRNA to an endothelial cell. The condition includes but is not limited to brain vascular diseases and brain tumors.
3	Mutant endonuclease V enzymes and applications thereof	US15048624	2016-02-19	US10100292B2	2018-10-16	John Richard Nelson; Robert Scott Duthie; Gregory Andrew Grossman; Anuradha Sekher
Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.
4	RNY-DERIVED SMALL RNAS AS BIOMARKERS FOR ATHEROSCLEROSIS-RELATED DISORDERS	US15030275	2014-10-20	US20160237500A1	2016-08-18	Michele TRABUCCHI; Laurent MARTINEZ; Emanuela REPETTO
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
5	Mutant endonuclease V enzymes and applications thereof	US13840062	2013-03-15	US09279150B2	2016-03-08	John Richard Nelson; Robert Scott Duthie; Gregory Andrew Grossman; Anuradha Sekher
Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.
6	MUTANT ENDONUCLEASE V ENZYMES AND APPLICATIONS THEREOF	US13840062	2013-03-15	US20140093878A1	2014-04-03	John Richard Nelson; Robert Scott Duthie; Gregory Andrew Grossman; Anuradha Sekher
Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.
7	The new toxin - antitoxin system	JP2011523998	2009-08-20	JP2012500027A	2012-01-05	正順井上; 良弘山口
ｍＲＮＡをＧＣＵで切断するｍＲＮＡインターフェラーゼの発現を誘導することを含む、細胞機能を阻害する方法が、或る特定の実施形態において開示される。
8	ENGINEERING MAMMALIAN GENOME USING DNA-GUIDED ARGONAUTE INTERFERENCE SYSTEMS (DAIS)	US15127128	2015-03-23	US20170198306A1	2017-07-13	Julien Valton; Philippe Duchateau
This invention relates to materials and methods for gene editing in mammalian cells, and more particularly to methods for gene editing using DNA-guided Argonaute (Ago) interference systems (DAIS) in T-cells.
9	MUTANT ENDONUCLEASE V ENZYMES AND APPLICATIONS THEREOF	US15048624	2016-02-19	US20160160198A1	2016-06-09	John Richard Nelson; Robert Scott Duthie; Gregory Andrew Grossman; Anuradha Sekher
Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.
10	Novel Toxin-Antitoxin System	US14259877	2014-04-23	US20140369988A1	2014-12-18	Masayori Inouye; Yoshihiro Yamaguchi
Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.
11	Novel Toxin-Antitoxin System	US13059893	2009-08-20	US20110217282A1	2011-09-08	Masayori Inouye; Yoshihiro Yamaguchi
Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.
12	RNY-DERIVED SMALL RNAS AS BIOMARKERS FOR ATHEROSCLEROSIS-RELATED DISORDERS	EP14786886.3	2014-10-20	EP3058089B1	2018-12-05	TRABUCCHI, Michele; MARTINEZ, Laurent; REPETTO, Emanuela
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
13	ENGINEERING MAMMALIAN GENOME USING DNA-GUIDED ARGONAUTE INTERFERENCE SYSTEMS (DAIS)	EP15712117.9	2015-03-23	EP3119897A1	2017-01-25	VALTON, Julien; DUCHATEAU, Philippe
This invention relates to materials and methods for gene editing in mammalian cells, and more particularly to methods for gene editing using DNA-guided Argonaute (Ago) interference systems (DAIS) in T-cells.
14	RNY-DERIVED SMALL RNAS AS BIOMARKERS FOR ATHEROSCLEROSIS-RELATED DISORDERS	EP14786886.3	2014-10-20	EP3058089A1	2016-08-24	TRABUCCHI, Michele; MARTINEZ, Laurent; REPETTO, Emanuela
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
15	NOVEL TOXIN-ANTITOXIN SYSTEM	EP09791747.0	2009-08-20	EP2340259A2	2011-07-06	INOUYE, Masayori; YAMAGUCHI, Yoshihiro
Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.
16	진균 감염 또는 뇌수막염 치료를 위한 ＵＰＲ 신호전달 유전자 ＩＲＥ1 및 ＨＸＬ1의 용도	KR1020100133885	2010-12-23	KR101311196B1	2013-09-27	반용선; 정광우; 강현아; 전선아
본 발명은 진균 감염 또는 뇌수막염 치료를 위한 UPR 신호전달 유전자 Ire1및 Hxl1의 용도에 관한 것이다. 보다 자세하게는 크립토코쿠스 네오포만스에서 새롭게 동정한 Ire1 및 Hxl1( H AC1 and X BP1 L ike gene 1) 단백질 및 이를 코딩하는 유전자의 기능을 손상시키는 경우, 항균 또는 뇌수막염 치료효과가 있음을 새롭게 밝혔다. 이를 기초로, 기존의 항균제 또는 뇌수막염 치료제와 병용투여시 상승효과를 가질 수 있는 후보물질을 스크리닝하여 새로운 항균 또는 뇌수막염 치료효과가 있는 약학조성물을 제공할 수 있다.
17	진균 감염 또는 뇌수막염 치료를 위한 ＵＰＲ 신호전달 유전자 ＩＲＥ1 및 ＨＸＬ1의 용도	KR1020100133885	2010-12-23	KR1020120072096A	2012-07-03	반용선; 정광우; 강현아; 전선아
PURPOSE: UPR signal transduction genes, Ire1 and Hxl1, are provided to improve antibacterial effect and to treat encephalomenigitis. CONSTITUTION: A method for screening an antibacterial agent comprises: a step of contacting a sample with cells containing Hxl1 proteins of sequence number 1 or Ire1 proteins of sequence number 3; a step of measuring the amount or activity of the proteins; and a step of determining the same is an antibacterial agent in case that the amount or activity of Hxl1 protein is down-regulated. An antibacterial pharmaceutical composition contains an antisense which is complement to a nucleotide sequence of sequence number 2 or 4 or siRNA oligonucleotide as an active ingredient.
18	USE OF UPR SIGNALING PATHWAY GENES IRE1 AND HXL1 FOR TREATMENT OF FUNGAL INFECTION AND MENINGITIS	PCT/KR2011009862	2011-12-20	WO2012087004A2	2012-06-28	BAHN YONG SUN; JUNG KWANG WOO; KANG HYUN AH; CHEON SEON AH
The present invention relates to the use of the UPR signaling pathway genes IRE1 and HXL1 for treatment of fungal infection and meningitis. In the invention, it was newly found that disruption of Ire1 and Hxl1 (HAC1 and XBP1-Like gene 1) proteins, newly identified in Cryptococcus neoformans, genes encoding the proteins, provides an antifungal effect and a meningitis-treating effect. Based on this finding, a candidate which can show a synergistic effect when being co-administered with an existing antifungal agent or meningitis-treating agent can be screened and a novel pharmaceutical composition having an antifungal effect and a meningitis-treating effect can be provided.
19	NOVEL TOXIN-ANTITOXIN SYSTEM	PCT/US2009054503	2009-08-20	WO2010022260A3	2010-07-01	INOUYE MASAYORI; YAMAGUCHI YOSHIHIRO
Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.

该功能需要专业版企业版VIP权限，您可以：